- Adare Pharma Solutions and Laxxon Medical are collaborating to offer cGMP 3D printing capabilities for oral dosage forms at Adare’s Pessano facility in Milan.
- The partnership will utilise Screen-Printed Innovative Drug (SPID®) Technology to produce complex pharmaceuticals with customised release profiles and improved bioavailability.
Adare Pharma Solutions, a global technology-driven CDMO, has announced a collaboration with Laxxon Medical, a pharma-technology company. This partnership will provide cGMP 3D printing capabilities at Adare’s Pessano facility in Milan, Italy.
The collaboration will leverage Screen-Printed Innovative Drug (SPID®) Technology, licensed from Exentis Group. This technology allows for the production of 3D-printed oral dosage forms with complex internal structures and a heterogeneous distribution of active ingredients. This will result in pharmaceuticals with customizable release profiles, improved bioavailability, and tailored pharmacokinetics.
A 3D printing system and a new bulk preparation mixer have been installed at the Pessano site, set to be fully operational by the end of Q4 2024. This cGMP suite will facilitate the scaling of Laxxon’s laboratory quantities to clinical trial material volumes directly, without altering the production process.
Tom Sellig, CEO of Adare Pharma Solutions, stated, “Our Pessano facility provides comprehensive CDMO solutions to customers in Europe, the United States, and Asia. Adare’s collaboration with Laxxon expands our ability to provide incredible dose flexibility options such as taste masking, solubility enhancement, shape modifications for ease of swallowing, and multiple APIs.”
Helmut Kerschbaumer, CEO of Laxxon Medical, added, “This partnership represents a significant step forward in actualizing our mission to drive disruptive global drug delivery and manufacturing solutions. Adare’s CDMO expertise and cGMP facilities will enable us to produce clinical samples efficiently for our partners and our own pipeline.”
The SPID® Technology, developed by Exentis Group, has been licensed exclusively to Laxxon for pharmaceutical applications. Adare’s Pessano facility, which spans 220,000 square feet (20,400 square meters), offers extensive R&D and manufacturing capabilities. A second clinical-scale 3D production system is planned for Adare’s Vandalia, Ohio facility, further extending the technology’s reach to key pharmaceutical markets.
Overview of outsourcing trends 
